- $4.19m
- $3.65m
Annual balance sheet for Oragenics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 17.6 | 27.3 | 11.4 | 3.48 | 0.865 |
| Net Total Receivables | — | 0.007 | 0 | — | — |
| Prepaid Expenses | |||||
| Total Current Assets | 18 | 27.7 | 14.3 | 3.87 | 1.47 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.698 | 0.524 | 0.469 | 0.01 | — |
| Other Long Term Assets | |||||
| Total Assets | 18.7 | 28.2 | 14.8 | 4.97 | 1.47 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 1.34 | 1.45 | 1.6 | 1.8 | 1.68 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1.84 | 1.74 | 1.75 | 1.8 | 1.68 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 16.8 | 26.5 | 13 | 3.17 | -0.212 |
| Total Liabilities & Shareholders' Equity | 18.7 | 28.2 | 14.8 | 4.97 | 1.47 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |